JonesTrading Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals (ATNMResearch Report), with a price target of $40.00. The company’s shares closed last Thursday at $11.43.

According to TipRanks.com, Roy is a 5-star analyst with an average return of 39.0% and a 57.1% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.

Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $43.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.47 and a one-year low of $4.71. Currently, Actinium Pharmaceuticals has an average volume of 513.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.